Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger

Mylan’s EpiPen has had a troubled few years—to say the least—with federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizer's generic business Upjohn working on a merger, a new EpiPen manufacturer could be in the cards.